These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30681656)

  • 1. Plazomicin (Zemdri) - a new aminoglycoside antibiotic.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):180-182. PubMed ID: 30681656
    [No Abstract]   [Full Text] [Related]  

  • 2. Plazomicin: an investigational therapy for the treatment of urinary tract infections.
    Karaiskos I; Souli M; Giamarellou H
    Expert Opin Investig Drugs; 2015; 24(11):1501-11. PubMed ID: 26419762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plazomicin: A Next-Generation Aminoglycoside.
    Shaeer KM; Zmarlicka MT; Chahine EB; Piccicacco N; Cho JC
    Pharmacotherapy; 2019 Jan; 39(1):77-93. PubMed ID: 30511766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
    Bilinskaya A; Linder KE; Kuti JL
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
    Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):117-118. PubMed ID: 39008106
    [No Abstract]   [Full Text] [Related]  

  • 9. Plazomicin for the treatment of patients with complicated urinary tract infection.
    McCarthy MW
    Drugs Today (Barc); 2018 Sep; 54(9):513-518. PubMed ID: 30303492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of complicated urinary tract infections. Comparative study of sisomicin and gentamicin.
    Madsen PO; Kjaer TB; Mosegaard A
    Urology; 1977 Jun; 9(6):635-8. PubMed ID: 329522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plazomicin-a new antibiotic for complicated urinary tract infections].
    Roschkow M
    Urologe A; 2019 Nov; 58(11):1348-1349. PubMed ID: 31659371
    [No Abstract]   [Full Text] [Related]  

  • 12. Plazomicin: A New Aminoglycoside.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2020 Feb; 70(4):704-709. PubMed ID: 31328228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):103-105. PubMed ID: 29913473
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro activity of plazomicin against quinolone-resistant gram-negative bacteria isolated from catheter-associated urinary tract infections.
    Abd-Elmonsef MME; Nagla S; Afandy ME; Maxwell SY
    J Chemother; 2021 Nov; 33(7):462-468. PubMed ID: 33810779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cefepime (maxipime) in the treatment of severe urinary tract infection].
    Derevianko II
    Antibiot Khimioter; 2003; 48(7):24-8. PubMed ID: 14628575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
    Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and clinical observations of sisomicin, a newly developed aminoglycoside derivative (author's transl)].
    Lode H; Kemmerich B; Koeppe P; Langmaack H
    Dtsch Med Wochenschr; 1975 Oct; 100(42):2144-50. PubMed ID: 1164890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.